Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults

Study Overview
=================
Brief Summary
-----------------
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.

Detailed Description
-----------------
Inclusion criteria pathologically confirmed BL or BL-U by World Health Organization 2008 criteria age >20 yrs received rituximab+chemotherapy as first-line treatment with measurable or evaluable lesion with complete set of clinical and laboratory data for the analysis

Official Title
-----------------
Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL

Conditions
-----------------
Burkitt's Lymphoma, High-grade B-cell Lymphoma

Intervention / Treatment
-----------------
* Other: No intervention (observational study)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL (BL-U) by WHO 2008 criteria age >20 yrs received rituximab+chemotherapy as first-line treatment with measurable or evaluable lesion Exclusion Criteria: 1. patients with BL or BL-U previously treated with rituximab

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Burkitt's Lymphoma<br>should be diagnosed pathologically by WHO 2008 criteria | Other: No intervention (observational study)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Event-free survival | Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death) | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete response rate | treatment response will be evaluated according to the Revised criteria for malignant lymphoma (Journal of Clinical Oncology 25:579-586) | 1-year | 
| overall survival | Overall survival is defined as the time from treatment initiation until death as a result of any cause | 1-year | 
| Grade 4 hematologic toxicities | toxicities will be graded according to Common Toxicity Criteria for Adverse Events (CTCAE) V.4.0. Hematologic toxicities planned to evaluated were; anemia (by hemoglobin), absolute neutrophil count, and platelet count | one year |